Haojie Chen1, Bowen Shi1, Yanyuan Wu1, Yuhang Qian1, Jiatong Zhou1, Xi Zhang2, Jie Ding3, Yongjiang Yu4. 1. Department of Urology, School of Medicine, Xinhua Hospital Affiliated to Shanghai Jiao Tong University, 1665 Kongjiang Rd, Yangpu, Shanghai, 200092, People's Republic of China. 2. Clinical Research and Innovation Unit, Xinhua Hospital of Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Rd, Yangpu, Shanghai, 200092, China. zhangxi@xinhuamed.com.cn. 3. Department of Urology, School of Medicine, Xinhua Hospital Affiliated to Shanghai Jiao Tong University, 1665 Kongjiang Rd, Yangpu, Shanghai, 200092, People's Republic of China. dingjie@xinhuamed.com.cn. 4. Department of Urology, School of Medicine, Xinhua Hospital Affiliated to Shanghai Jiao Tong University, 1665 Kongjiang Rd, Yangpu, Shanghai, 200092, People's Republic of China. yuyongjiang@xinhuamed.com.cn.
Abstract
OBJECTIVES: To compare the accuracy of several volume and diameters modified prostate health index (mPHI) models with PHI density (PHID), PHI, and other prostate-specific antigen (PSA) derivatives in detecting PSA grey zone prostate cancer (PCa). MATERIALS AND METHODS: Between August 2020 and September 2021, a consecutive cohort of 214 suspected PCa patients with elevated total PSA values ranged from 4.0 to 10.0 ng/mL were prospectively recruited and received PHI detections and transrectal ultrasonography (TRUS) measurements, followed by systematic prostate biopsies confirmation. RESULTS: Among the 214 patients enrolled in the project, a total of 80 were diagnosed with PCa. In univariate analysis for the training cohort, the area under curve (AUC) of mPHI-2 [Formula: see text] was 0.8310, which outperformed PHID in identifying PSA grey zone PCa (P ≤ 0.0001) and showed the best net benefit in decision curve analysis (DCA). By a threshold of 0.2835, the sensitivity and specificity in the prediction of PCa were 78.9% and 90.3%, while the positive predictive value (PPV) and negative predictive value (NPV) were 78.3% and 78.6%, respectively. CONCLUSIONS: According to our present single-center experience, the mPHI-2 risk predictor outperformed PHID or other classical parameters alone in the PCa detection with a grey zone PSA level in Asian males.
OBJECTIVES: To compare the accuracy of several volume and diameters modified prostate health index (mPHI) models with PHI density (PHID), PHI, and other prostate-specific antigen (PSA) derivatives in detecting PSA grey zone prostate cancer (PCa). MATERIALS AND METHODS: Between August 2020 and September 2021, a consecutive cohort of 214 suspected PCa patients with elevated total PSA values ranged from 4.0 to 10.0 ng/mL were prospectively recruited and received PHI detections and transrectal ultrasonography (TRUS) measurements, followed by systematic prostate biopsies confirmation. RESULTS: Among the 214 patients enrolled in the project, a total of 80 were diagnosed with PCa. In univariate analysis for the training cohort, the area under curve (AUC) of mPHI-2 [Formula: see text] was 0.8310, which outperformed PHID in identifying PSA grey zone PCa (P ≤ 0.0001) and showed the best net benefit in decision curve analysis (DCA). By a threshold of 0.2835, the sensitivity and specificity in the prediction of PCa were 78.9% and 90.3%, while the positive predictive value (PPV) and negative predictive value (NPV) were 78.3% and 78.6%, respectively. CONCLUSIONS: According to our present single-center experience, the mPHI-2 risk predictor outperformed PHID or other classical parameters alone in the PCa detection with a grey zone PSA level in Asian males.
Authors: Flip H Jansen; Ron H N van Schaik; Joep Kurstjens; Wolfgang Horninger; Helmut Klocker; Jasmin Bektic; Mark F Wildhagen; Monique J Roobol; Chris H Bangma; Georg Bartsch Journal: Eur Urol Date: 2010-02-13 Impact factor: 20.096
Authors: William J Catalona; M'liss A Hudson; Peter T Scardino; Jerome P Richie; Frederick R Ahmann; Robert C Flanigan; Jean B DeKernion; Timothy L Ratliff; Louis R Kavoussi; Bruce L Dalkin; W Bedford Waters; Michael T MacFarlane; Paula C Southwick Journal: J Urol Date: 1994-12 Impact factor: 7.450